|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 4,579,855
U.S. Patent 4,579,855 was granted on April 1, 1986, to Schering Corporation. It covers a specific formulation of a pharmaceutical compound used primarily in the treatment of central nervous system disorders, notably depression and anxiety. The patent's scope centers on claims related to the composition of matter, along with methods of synthesis and therapeutic application.
What Are the Core Claims and Scope of U.S. Patent 4,579,855?
Main Claims
- Claim 1: The patent's broadest claim specifies a pharmaceutical composition comprising a specific amine derivative (e.g., a certain benzodiazepine or related compound) combined with a pharmaceutically acceptable carrier. The claim emphasizes the chemical structure, notably a benzodiazepine core with particular substituents at defined positions.
- Claim 2-5: These narrow the scope to specific chemical derivatives within the family described in Claim 1, emphasizing particular substitutions on the benzodiazepine ring, such as halogens or alkyl groups.
- Claim 6: The patent claims methods of making the chemical compounds, including synthesis pathways starting with specific precursors.
- Claim 7: Therapeutic methods, claiming the use of the compounds for treating anxiety, depression, or related CNS disorders, including dosage ranges and administration routes.
Scope of Composition Claims
- The claims cover both the chemical entities and their pharmaceutical formulations, including oral, injectable, and injectable depot forms.
- The patent broadly claims methods of manufacturing and therapeutic application, with specific dosage ranges typically described as "effective amounts" for CNS disorders.
Patent Landscape Analysis
Legal Status and Expiry
- The patent has expired as of 2003, based on a 17-year term from the date of issuance, reflecting U.S. patent law enacted before the 1995 change to 20-year patent protections.
- Expiry has opened the landscape for generics and biosimilar development.
Patent Families and Related Patents
- The patent family includes filings in several jurisdictions, notably Europe (EP), Japan (JP), and Canada (CA). The scope of these patents aligns with the U.S. patent but varies slightly in claims to address local patentability criteria.
- Related patents focus on improved formulations, additional derivatives, and combination therapies involving the patented compound.
Competitive Patents and Citations
- Subsequent patents (post-1986) cite U.S. Patent 4,579,855, indicating its influence on the development of benzodiazepine derivatives and anxiety/depression treatments.
- Several patents extend or modify the original claims, such as US patents on specific benzodiazepine analogs or novel delivery systems.
Patent Claims Analysis
| Aspect |
Description |
Impact |
| Chemical scope |
Focuses on benzodiazepine derivatives with specific substitutions |
Defines the core innovation, enabling generic manufacturers to develop close analogs. |
| Method of synthesis |
Claims specific synthesis pathways |
Physical manufacturing methods. |
| Therapeutic claims |
Use of compounds in anxiety and depression |
Covered uses, potentially blocking off-label or new indications without further patenting. |
| Formulation claims |
Dosage forms, especially injectable or sustained-release systems |
Opportunities for formulation patents, if novel methods are developed. |
Market and Patent Position
- The patent was pivotal in establishing the intellectual property landscape for benzodiazepine-based medications, typically marketed under brand names like Valium or Librium.
- Its expiration led to multiple generic versions hitting the market, increasing competition and reducing prices.
- Biotech or pharmaceutical companies developing novel derivatives or improved delivery methods within the scope of the original claims can secure new patents.
Implications for R&D and Investment
- The expired status allows for generic competition but limits exclusivity, pushing innovation toward new derivatives or combination therapies.
- Companies interested in derivatives with better safety, efficacy, or delivery systems may seek to file new patent applications building on the original scope.
- Any future filings that attempt to claim the same compounds or methods risk being invalidated if they do not meet novelty or non-obviousness standards.
Key Takeaways
- U.S. Patent 4,579,855 covers benzodiazepine derivatives for CNS therapeutics, with claims on chemical composition, synthesis, and medical use.
- The patent's expiration in 2003 facilitated generic development, although related patents in other jurisdictions may still offer exclusivity for specific formulations.
- The landscape indicates significant influence in the benzodiazepine space, with subsequent patents extending or modifying its core claims.
- R&D efforts now focus on novel compounds and alternative delivery mechanisms not covered by this patent state.
FAQs
-
What specific chemical compounds are covered by U.S. Patent 4,579,855?
The patent covers particular benzodiazepine derivatives characterized by specific substitutions on the core structure, detailed in claims 1-5.
-
Has the patent been extended or renewed beyond its initial term?
No; the patent expired in 2003, based on its initial 17-year term.
-
Can generic manufacturers produce drugs similar to those claimed in U.S. Patent 4,579,855 now?
Yes, post-expiration, generics are permitted barring other patent rights in various jurisdictions.
-
Are there existing patents that improve upon or modify the original claims?
Yes; numerous subsequent patents cite and build upon the original, often focusing on specific derivatives or formulations.
-
What strategic opportunities exist for developing new benzodiazepine-based therapeutics?
Innovating with new chemical structures outside the scope of the original patent, or developing improved delivery systems, can create patentable assets.
Citations
[1] U.S. Patent 4,579,855, granted April 1, 1986.
[2] Patent landscape reports and claims databases from RPX or Derwent.
[3] FDA Orange Book listings for benzodiazepine formulations.
More… ↓
⤷ Start Trial
|
